Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Verve Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results heart-1 Initial Clinical Data Expected in the Fourth Quarter of 2023 Preclinical Studies and Clinical Operations Activities Underway to Support Initiation of Clinical Trials for VERVE-102 and VERVE-201 in 2024 Lp Program Advancing in Collaboration with Lilly; Received $60 Million in Combined Upfront Payment and Equity Investment in August 2023 Well-capitalized with Cash Runway into 2026"
06/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/15/2023 8-K Quarterly results
Docs: "Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results heart-1 Clinical Trial of VERVE-101 Ongoing with Initial Data Expected in the Second Half of 2023 VERVE-102 Named Second PCSK9-Targeting Program, Leveraging Novel GalNAc-LNP Delivery with Clinical Trial Initiation Expected in the First Half of 2024 VERVE-201 Targeting ANGPTL3 Progressing with Clinical Trial Initiation Expected in the Second Half of 2024 Well-capitalized with $508.7 Million Supporting Runway into the Second Half of 2025"
03/02/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results heart-1 Clinical Trial of VERVE-101 Ongoing in New Zealand and UK; Data from Dose Escalation Cohorts Expected in the Second Half of 2023 VERVE-201 Progressing Through Preclinical Development with Clinical Initiation Anticipated in 2024 Well-Capitalized with $554.8 Million Supporting Runway into the Second Half of 2025"
12/05/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/07/2022 8-K Quarterly results
Docs: "Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results VERVE-101 Investigational New Drug Application Placed on Hold by U.S. Food and Drug Administration Dosing Completed in First Dose Cohort of the heart-1 Clinical Trial of VERVE-101 in Patients with HeFH; Independent Data Safety Monitoring Board Recommended Proceeding to Second Dose Level in New Zealand and U.K. Well-capitalized with $550.7 Million Supporting Runway into Second Half of 2025"
08/09/2022 8-K Quarterly results
07/21/2022 8-K Quarterly results
07/21/2022 8-K Quarterly results
07/20/2022 8-K Quarterly results
07/12/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
07/07/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/14/2022 8-K Quarterly results
11/29/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/10/2021 8-K Quarterly results
Docs: "Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results"
08/24/2021 8-K Quarterly results
08/12/2021 8-K Quarterly results
06/21/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy